Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

Last updated: April 25, 2024
Sponsor: Ciusss de L'Est de l'Île de Montréal
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma

Treatment

EBV-specific T cells

Clinical Study ID

NCT06391814
2024-3579
  • Female

Study Summary

Single-patient trial aiming to provide immunological consolidation following allogeneic stem cell transplantation to a young adult patient suffering from a systemic EBV-positive lymphoma of childhood.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Capacity to provide informed consent
  2. Age ≥ 18
  3. Negative serum pregnancy test and use of effective contraception method.

Exclusion

Exclusion Criteria:

  1. Administration within less than 28 days of T-cell depleting antibodies (ATG, OKT3,Campath)
  2. Pregnancy
  3. Any abnormal condition or laboratory result that is considered by the PrincipalInvestigator capable of altering patient or study outcome.
  4. Active uncontrolled GVHD (acute GVHD grade II-IV or progressive extensive chronicGVHD) at time of enrolment or infusion.

Study Design

Total Participants: 1
Treatment Group(s): 1
Primary Treatment: EBV-specific T cells
Phase:
Study Start date:
January 16, 2024
Estimated Completion Date:
April 05, 2025

Study Description

Following a presumed primary EBV infection, a 19 year old female patient rapidly suffered systemic inflammatory response, hemophagocytosis, multi-organ failure and evidence of EBV+ T-cell lymphoma.

The patient was aggressively treated and responded to SMILE-based chemotherapy. Once complete response was ascertained by PET imaging, the patient underwent myeloablative HLA-matched unrelated allogeneic stem cell transplantation (cyclophosphamide 60mg/Kg, total body irradiation - 12Gy with anti-thymocyte globulin). The stem cell donor had a positive serology for EBV (IgG).

The patient's EBV titer was weakly positive at the time of transplantation. A decision was made to offer consolidative treatment consisting of donor-derived ex vivo expanded EBV-reactive T cells following transplantation.

A EBV-specific T-cell line was manufactured from a portion of the cryopreserved G-CSF mobilized peripheral graft after appropriate authorizations were obtained.

The patient suffered a severe episode of intestinal graft-versus-host disease early following transplantation but received a first dose of EBV-reactive T cells (20x10e6 T cells/meter square of body surface area 5 months post-transplantation

Connect with a study center

  • Ciusss-Emtl

    Montréal, Quebec H1T 2M4
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.